induce a specific T-cell immunity to the mutant protein or fragment thereof.

A1 Cont

71. A method for treating a human patient afflicted with cancer comprising stimulating the patient *in vivo* or *ex vivo* with a peptide according to any of claims 34-48.--

REMARKS

Applicants request early examination on the merits and favorable consideration of this application.

Claims 33-71 are presently pending in this application, with claim 33 being independent. Claims 1-32 as originally filed in the parent PCT application (i.e., International Application No. PCT/NO99/00143 (or International Publication No. WO 99/58552)) have been cancelled without prejudice to or disclaimer of the subject matter recited in those claims.

Newly added claims 33-71 substantially mirror claims 1-34 that were proposed during international preliminary examination of the parent PCT application pursuant to Article 34 of the Patent Cooperation Treaty. A copy of the Article 34 claim amendments is annexed to the International Preliminary Examination Report that is being submitted herewith. These claims were rewritten as claims 33-71 to place them in better

form under U.S. patent practice. The rewritten claims, for example, avoid improper multiple dependent claims and other objectionable claim forms. Some multiple dependent claims were also removed to reduce the overall claim count on which the patent fees are based. No new matter has been added by these claim amendments.

The specification also has been amended to correct obvious typographical errors. Applicants submit that no new matter has been added by these specification amendments. Most of the corrections involve erroneous gene sequence identification numbers on pages 40-42. Support for the corrections can be found, for example, at pages 22-24 of the specification. The following table sets out specific locations on those pages in the specification where the proper sequence information for each noted genetic sequence is provided. The genes are listed in the order that they are mentioned at pages 40-42 of the specification.

Name of Gene	SEQ. ID NOs.	Page, Line No.
Human hMSH6 gene	200-203 and 293-297	Page 22, Line 25
Human n-myc gene	189-194	Page 22, Line 23
Human p53 associated gene	285-292	Page 23, Line 10
Human BRCA1-associated RING domain protein (BARD1) gene	404-417	Page 24, Line 5

Human MUC1 gene	247-266	Page 23, Line 3
Human germline n-myc gene	182-188	Page 22, Line 22
Human nasopharynx carcinoma EBV BNLF-1 gene	204-210	Page 22, Line 27
Human transforming growth factor-beta induced gene product (BIGH3)	227-232	Page 22, Line 33
Human neurofibromin (NF1) gene	176-181	Page 22, Line 21
b-raf oncogene	170-175	Page 22, Line 20
Human protein-tyrosine kinase (JAK1) gene	267-271	Page 23, Line 5
Human protein-tyrosine kinase (JAK3) gene	272-279	Page 23, Line 7
Human malignant melanoma metastasis-supressor (hKiSS-1) gene	328-334	Page 23, Line 24
Human metastasis-associated mta1 (hMTA1) gene	357-362	Page 23, Line 29
Human kinase (TTK) gene	109-120	Page 22, Line 9
Human transcriptional repressor (CTCF) gene	121-127	Page 22, Line 10
Human cell cycle regulatory protein (E1A-binding protein) p300 gene	211-218	Page 22, Line 29
Human FLt4 gene (for transmembrane tyrosinase kinase)	280-284	Page 23, Line 9
Human G protein-coupled receptor (hGPR1) gene	314-319	Page 23, Line 18
Human transcription factor (hITF-2) gene	326-327	Page 23, line 22
Human telomerase-associated protein TP-1 (hTP-1) gene	335-348	Page 23, Line 26
Human transcription factor TFIIB 90 kDa subunit (hTFBIIB90) gene	363-369	Page 23, Line 31
Human FADD-homologous ICE/CED-3like protease gene	128-133	Page 22, Line 13

Human retinoblastoma binding protein 1 isoform I (hRBP1) gene	148-156	Page 22, Line 17
Human neurofibromin (NF1) gene	176-181	Page 22, Line 21
Human p53 associated gene	285-292	Page 23, Line 10
Human retinolastoma related protein (p107) gene	310-313	Page 23, Line 16
Human tumour suppessor (hLUCA-1) gene	370-377	Page 23, Line 33
Human can (hCAN) gene	298-300	Page 23, Line 11
Human dek (hDEK) gene	307-309	Page 23, Line 14
Human DBL (hDBL) proto-oncogene/Human MCF2PO (hMCF2PO) gene	301-306	Page 23, Line 13

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,

John W. Behringer
Reg. No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200
NMD\vjw